Glenmark Pharmaceuticals Ltd has a significant presence in the branded generics market in all emerging economies including India. The company entered the dermatology market with the launch of Candid cream. Glenmark's pioneering drug development focuses primarily on inflammation [asthma/COPD, rheumatoid arthritis, etc.], metabolic disorders [diabetes, obesity, etc.] and pain [neuropathic pain and inflammatory pain]. The company's formulation business focuses on therapeutic areas, e.g. dermatology, infectious medicine, respiratory, cardiac, diabetes, gynecology, central nervous system and oncology. India is the organization's largest market region by revenue.